Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Dana-Farber Cancer Institute |
---|---|
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00113646 |
The purpose of this study is to determine if recipients of non-myeloablative ex-vivo T-cell depleted peripheral blood (PBSC) stem cell transplantation using a mismatched related donor will have less severe graft versus host disease (GVHD), transplant related mortality, and less graft failure compared to alternative haploidentical stem cell transplantation.
Condition | Intervention | Phase |
---|---|---|
Lymphoma Leukemia Multiple Myeloma Myelodysplastic Syndrome |
Drug: MEDI-507 Procedure: Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study |
Official Title: | Non-Myeloablative HLA-Mismatched Ex-Vivo T-Cell Depleted Stem Cell Transplantation for Hematologic Malignancies |
Estimated Enrollment: | 30 |
Study Start Date: | November 2002 |
Estimated Study Completion Date: | December 2007 |
Estimated Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
One major obstacle to further advancement in the role of bone marrow transplant (BMT) in hematological malignancies is graft-versus-host-disease (GVHD), which can best be prevented by removing T-cells from the donor stem cell product. However, previous experience with T-cell depletion has been associated with an increased rate of engraftment failure and leukemic relapse. Another obstacle is that a large fraction of leukemia and lymphomas afflict older patients who are more prone to GVHD and have co-morbid conditions that prevent them from being a candidate for BMT.
This trial uses a non-myeloablative conditioning regimen with cyclophosphamide, MEDI-507, fludarabine, and thymic irradiation followed by a T-cell depleted PBSC infusion. Cyclosporine is used for GVHD prophylaxis, and tapered beginning on day 35. Data from our mouse model and previous clinical trials have demonstrated that this approach can induce mixed chimerism without GVHD, with the potential for conversion of mixed chimerism to full donor hematopoiesis following donor leukocyte infusions.
Ages Eligible for Study: | up to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02116 |
Principal Investigator: | Thomas Spitzer, M.D. | Massachusetts General Hospital, Harvard University |
Responsible Party: | Massachusetts General Hospital ( Thomas Spitzer MD ) |
Study ID Numbers: | 02-163 |
Study First Received: | June 9, 2005 |
Last Updated: | December 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00113646 |
Health Authority: | United States: Food and Drug Administration |
Non-Myeloablative T-cell Depleted Mismatched Stem Cell Transplantation |
Hematologic Neoplasms Precancerous Conditions Blood Protein Disorders Paraproteinemias Cyclophosphamide Hemostatic Disorders Leukemia Preleukemia Hemorrhagic Disorders Multiple myeloma Lymphoma Myelodysplastic syndromes Immunoproliferative Disorders |
Hematologic Diseases Blood Coagulation Disorders Myelodysplastic Syndromes Myelodysplasia Vascular Diseases Fludarabine monophosphate Multiple Myeloma Lymphatic Diseases Fludarabine Lymphoproliferative Disorders Bone Marrow Diseases Neoplasms, Plasma Cell |
Neoplasms Neoplasms by Site Pathologic Processes Disease |
Neoplasms by Histologic Type Immune System Diseases Syndrome Cardiovascular Diseases |